We need full transparency on vaccine approvals & on EU’s vaccination strategy

The European Medicines Agency's (EMA) approval of a second Covid vaccine, Moderna, is another step forward in tackling the pandemic. Renew Europe has strongly defended the reinforcement of the EMA's role in this, which is vital to combine trust in the science, speed in application and solidarity across all EU member states.

The EU's strategy of negotiating purchases as one bloc, having a balanced portfolio and not cutting corners on the scientific approval process is undoubtedly the right one, but Renew Europe calls for enhanced transparency from the EMA and the European Commission on the way forward. Renew Europe calls on the EMA and the European Commission to provide a clear explanation of current approval processes, purchases and a timetable of next steps; we will request that this item is added to the agenda of the January Plenary. 
 
President of Renew Europe, Dacian Cioloș, said: 'The approval of a second vaccine is good news and I count on the EMA to clearly explain its decisions and timetable for the next vaccines. I will ask for a debate in the European Parliament on the vaccination process. It is very important that citizens have clarity not only on the efficiency and deployment of the vaccine but also on the approval process, on when they can realistically expected to get it and in what conditions. Transparency and sound, factual communications are the best medicine, not only against conspiracy theories, but also to build trust in the EU institutions.'

'The EU needs to be more effective in countering disinformation and distrust. This needs close cooperation between the Commission, the EMA and national governments. The current amount of conflicting stories and fake news about the vaccines is shocking and needs a better answer.’